Related Experiment Videos
[Therapeutic strategy in severe encephalopathies].
1Servicio de Neuropediatría.; Hospital Clínico Universitario San Carlos, Madrid, 28040, España. jcampos@hcsc.insalud.es
Revista De Neurologia
|June 26, 2001
Summary
Severe infantile epilepsy syndromes are often drug-resistant with poor cognitive outcomes. While some treatments show limited success in West syndrome and Lennox-Gastaut syndrome, neonatal myoclonic encephalopathies and Dravet syndrome have limited therapeutic viability.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Neuroscience
Context:
- Severe epileptic syndromes in infancy present significant challenges due to drug resistance and poor prognosis.
- These conditions, including neonatal myoclonic encephalopathies, West syndrome, and Lennox-Gastaut syndrome, require precise electroclinical differentiation.
- Understanding the nuances of these syndromes is crucial for developing effective management strategies.
Purpose:
- To review the electroclinical semiology and therapeutic strategies for severe infantile epileptic syndromes.
- To evaluate the efficacy of current treatments, including pharmacological and surgical options.
- To differentiate between various infantile epilepsy syndromes and their respective prognoses.
Summary:
- Neonatal myoclonic encephalopathies and severe myoclonic epilepsy of childhood show limited therapeutic response.
- West syndrome and Lennox-Gastaut syndrome exhibit variable treatment outcomes, influenced by etiology.
- Cryptogenic forms of West and Lennox-Gastaut syndromes offer better seizure control (20-30%) but with only 5-9% achieving normal intelligence.
Impact:
- Highlights the limited efficacy of current treatments for certain severe infantile epilepsies.
- Emphasizes the importance of etiology in predicting treatment success for West and Lennox-Gastaut syndromes.
- Underscores the poor cognitive outcomes even with seizure control in these challenging pediatric epilepsy conditions.